**Open Access** 

# Immune cells mediate the effects of gut microbiota on neuropathic pain: a Mendelian randomization study



Hao Pan<sup>1</sup>, Cheng-xiao Liu<sup>1</sup>, Hui-juan Zhu<sup>2</sup> and Guang-fen Zhang<sup>1\*</sup>

# Abstract

**Background** The gut microbiota may be involved in neuropathic pain. However, the causal association between gut microbiota and neuropathic pain remains unclear. Whether immune cells and inflammatory factors mediate the pathway from gut microbiota to neuropathic pain has not been elucidated.

**Methods** We obtained the summary data of 412 gut microbiota, 731 immune cells, 91 inflammatory factors, and five types of neuropathic pain (drug-induced neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, and unspecified neuralgia) from large-scale genome-wide association study (GWAS) datasets and the FinnGen database. We used bidirectional Mendelian randomization (MR) analysis to explore the causal association between gut microbiota and neuropathic pain. Additionally, we conducted a mediation analysis to identify whether immune cells and inflammatory factors act as mediators within these causal relationships.

**Results** Our study revealed 30 causal relationships between 26 gut bacterial taxa and five types of neuropathic pain, including four associated with drug-induced neuropathy, six with postherpetic neuralgia, five with sciatica, eight with trigeminal neuralgia, and seven with unspecified neuralgia. Moreover, we identified 35 gut bacterial pathway abundances causally involved in neuropathic pain. The reverse MR analysis showed no evidence of reverse causality from gut microbiota to neuropathic pain. Mediation analysis demonstrated that the immune cell phenotype "HLA-DR<sup>++</sup> monocyte % leukocyte" mediated the causal relationship between p\_Proteobacteria and sciatica with a mediation proportion of 36.15% (P=0.038), whereas "CD11c on CD62L<sup>+</sup> myeloid dendritic cell" mediated the causal pathway from assimilatory sulfate reduction to trigeminal neuralgia with a mediation proportion of 27.90% (P=0.041).

**Conclusion** This study identified the causal relationships between several specific gut microbiota and various neuropathic pain subtypes. Additionally, two immune cells may act as potential mediators in the pathways from gut microbiota to neuropathic pain.

Keywords Gut microbiota, Immune cells, Inflammatory factor, Neuropathic pain, Mendelian randomization

\*Correspondence: Guang-fen Zhang

wfzhgf87@126.com

<sup>1</sup>Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, PR China <sup>2</sup>Department of Anesthesiology, Jinan Seventh People's Hospital, Jinan 250021, Shandong, PR China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

# Background

Neuropathic pain is a common chronic condition characterized by sustained, irreversible pain caused by a lesion or disease of the somatosensory system involving the peripheral and central neurons [1, 2]. It is caused by various etiologies, including traumatic injuries, infections, diabetes, and exposure to toxins, such as chemotherapy agents [3]. Most patients with neuropathic pain experience either continuous or intermittent spontaneous pain, which may be accompanied by hyperalgesia, allodynia, aftersensations, and referred pain [2]. Neuropathic pain may induce sleep disturbances, fatigue, and emotional disorders, resulting in an imbalance in work, leisure activities, and family relationships [1]. However, the mechanisms underlying neuropathic pain have not been elucidated, resulting in a lack of effective drugs and methods for its treatment.

In humans, the gastrointestinal tract is a vast, populous, and complex microbial ecosystem estimated to contain>10<sup>14</sup> microorganisms, including archaea and eukaryotes, but predominantly bacteria [4, 5]. Substantial evidence strongly demonstrated that neuropathic pain may lead to disturbance of gut microbiota [6], which plays a crucial role in neuropathic pain processes [1]. However, current studies, primarily observational and preclinical, showed inconsistent results. One study suggested that pain was exacerbated after transplanting fecal microbiota from anhedonia-susceptible spared nerve injury (SNI) rats into antibiotic-treated pseudo-germfree mice, whereas microbiota from resilient SNI rats significantly improved pain [7]. Ma et al. reported that depleting the gut microbiota in mice with various antibiotics prevented or completely suppressed mechanical allodynia and thermal hyperalgesia induced by chronic constriction injury (CCI), oxaliplatin, or streptozotocin [8]. Conversely, an observational study indicated that fluoroquinolone or amoxicillin-clavulanate intake increased the incidence of peripheral neuropathy [9]. Nevertheless, the causal relationship between gut microbiota and neuropathic pain remains unclear.

Interestingly, gut microbiota may regulate immune cells and cytokines, whereas immune cells and inflammation play vital roles in neuropathic pain processes [10–12]. Gut microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), inhibit macrophages activation through negatively regulating the NLRP3 inflammatory signaling pathway [13]. In addition, macrophages contribute to the initiation and maintenance of mechanical hypersensitivity in neuropathic pain [14]. In a recent study, gut microbiota may reduce CCI-induced neuropathic pain by regulating T cells to shift from a pro-inflammatory to an anti-inflammatory profile [15]. Thus, we hypothesized that immune cells and inflammatory

factors may be mediators in the relationship between gut microbiota and neuropathic pain.

Mendelian randomization (MR) is a widely accepted method to infer causal relationships between exposures and outcomes by utilizing single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) in genetic studies [16]. Due to the random assignment of SNPs at conception, MR can simulate a randomized controlled experiment, avoiding reverse causality bias and reducing confounding factors in conventional epidemiological and observational studies [17, 18]. We initially conducted a bidirectional two-sample MR analysis to explore the causal effects of gut microbiota on neuropathic pain. Subsequently, we adopted a mediation analysis to determine whether immune cells and inflammatory factors may mediate the causal relationships between gut microbiota and neuropathic pain.

# Methods

#### Study design

The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology Mendelian Randomization (STROBE-MR) guidelines [19, 20]. MR is based on three core principles: (1) relevance hypothesis: IVs should be strongly associated with exposure (gut microbiota, immune cells, and inflammatory factors); (2) independence hypothesis: IVs are irrelevant to confounding factors; (3) exclusivity hypothesis: IVs affect outcomes (NP) exclusively through their effect on the exposure [21]. Figure 1 shows the study diagram.

#### Data source

We obtained new data on 412 gut microbiota from the study by Esteban et al., involving 7738 participants and analyzing 207 taxa (including 5 phyla, 10 classes, 13 orders, 26 families, 48 genera, and 105 species) and 205 pathways reflecting microbial composition and activity [22]. We obtained the genome-wide association study (GWAS) summary data on 731 immune cell traits from Orrù et al. [23]. This dataset includes 3757 individuals of European ancestry with no overlapping cohorts. The immune features measured were absolute cell counts (AC, n=118), median fluorescence intensity for surface antigens (MFI and SAL, n=389), morphological parameters (MPs, n=32), and relative cell counts (RCs, n=192). The MFI, AC, and RC features cover mature stages of various immune cells: B cells, cDCs, T cells, monocytes, myeloid cells, TBNK cells (T cells, B cells, and natural killer cells), and Treg cells. The MP features specifically include cDC and TBNK panels. In addition, the plasma protein quantitative trait loci (pQTL) data of 91 inflammatory factors were obtained from Zhao et al.'s study [24]. Considering the higher prevalence of peripheral neuropathic pain, we obtained the available GWAS



Fig. 1 Study design overview

summary statistics for the five types of neuropathic pain (drug-induced neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, and unspecified neuralgia) from the FinnGen R10 database (https://r10.finngen.fi/) [25]. Compared with a recent study [26], we used the same version of FinnGen R10 dataset for trigeminal neuralgia, whereas we included more recent data for postherpetic neuralgia and expanded our analysis to cover three additional types: drug-induced neuropathy, sciatica, and unspecified neuralgia. Detailed data source information is provided in Additional file 1: Table S1. No additional ethical review was required for our study because ethical approval for the original GWAS studies was granted.

#### Instrumental variable selection

First, we set the significance threshold of  $P < 5 \times 10^{-8}$  to select SNPs as IVs related to 731 immune cells and 91 inflammatory factors. Owing to the limited number of SNPs related to gut microbiota identified under the  $P < 5 \times 10^{-8}$  threshold, a more lenient threshold of  $P < 1 \times 10^{-5}$  was used to select SNPs related to the gut microbiota. Second, a linkage disequilibrium (LD) analysis of SNPs was conducted to ensure independence among SNPs with thresholds of  $r^2 < 0.001$  and 10,000 kb distance. Third, we removed palindromic SNPs after harmonization with the outcome's GWAS summary statistics to ensure consistency between effect alleles and sizes. Fourth, the genetic variance explained (R<sup>2</sup>) and F-statistic

for each SNP were calculated to estimate the strength of the selected SNPs, and SNPs with F-statistic < 10 were removed to reduce weak instrumental bias [27]. We calculated R<sup>2</sup> as  $2 \times (1-MAF) \times MAF \times beta^2$  (where MAF is the minor allele frequency and beta is the effect size on the exposure) and F-statistic as  $F=R^2 \times (N-2)/(1-R^2)$ , where N is the effective sample size [28].

#### **MR** analysis

MR analysis was conducted to evaluate the causal effects of gut microbiota, immune cells, and inflammatory factors on neuropathic pain. To ensure robustness, the inverse variance weighted (IVW) method was used as the primary analysis approach, with MR-Egger, weighted median, weighted mode, debiased IVW, and robust adjusted profile score (RAPS) as supplementary methods. Additionally, the Wald ratio method was applied for exposures that include only one SNP. IVW performs a meta-analysis of Wald ratios from each SNP, ensuring the robustness of the estimates in the absence of pleiotropy [29, 30]. The weighted median method can provide consistent and unbiased causal estimates in the presence of horizontal pleiotropy, even when 50% of the instrumental variables were invalid [31]. The weighted mode method weighs SNP effect estimates by their inverse variance and selects the most common weighted effect as the final causal estimate, ensuring robustness against pleiotropy and invalid SNPs [32]. The MR-Egger method is based

on a regression model that allows for pleiotropy and can generate unbiased estimates even with invalid IVs [33]. The debiased IVW method ensures the robustness of the results with the introduction of weak instrument bias [34]. RAPS effectively addresses both systematic and idiosyncratic pleiotropies, ensuring robust inferences for MR analysis with many weak instruments [35]. When the estimates of the IVW method met a threshold of P < 0.05, and the effect directions were consistent across all these methods, the results were considered statistically significant and robust, including them for further analysis.

In the sensitivity analysis, we adopted various approaches to evaluate the robustness of the results. Cochrane's Q test was performed to detect heterogeneity among the selected SNPs, and P<0.05 indicated heterogeneity [29]. Moreover, the MR-Egger intercept and MR-PRESSO global test were conducted to assess the potential horizontal pleiotropy [33, 36]. Additionally, MR-PRESSO could identify outliers that may influence horizontal pleiotropy [36]. After pleiotropic SNP removal, a subsequent reanalysis can be conducted to ensure more accurate and robust results. Additionally, a leave-one-out analysis was performed to assess the stability of the causal associations and identify the influence of any single SNP on the results [37].

## **Mediation analysis**

We screened potential mediators in the causal pathway from gut microbiota to neuropathic pain through the following steps: First, we identified gut microbiota, immune cells, and inflammatory factors with significant causal associations with neuropathic pain and showed no heterogeneity or pleiotropy. Second, we explored the causal effects of gut microbiota on immune cells and inflammatory factors based on the same criteria. Third, we retained logically consistent potential mediators based on the directions of the effect values: gut microbiota-neuropathic pain ( $\beta$ ), gut microbiota–immune cells and inflammatory factors ( $\beta$ 1), and immune cells and inflammatory factors–neuropathic pain ( $\beta$ 2). If  $\beta$  was positive, both  $\beta$ 1 and  $\beta 2$  are either positive or negative. Conversely, if  $\beta$  was negative, either  $\beta 1$  or  $\beta 2$  should be positive and the other negative. Subsequently, we calculated the mediation effect using the product of coefficients method ( $\beta 1 \times \beta 2$ ) and estimated the proportion of mediation by dividing the mediation effect by the total effect  $[(\beta 1 \times \beta 2) / \beta]$ . The delta method was used to estimate the 95% confidence interval (CI) for the mediation effect [38]. A P-value of <0.05 was indicative of significant mediation effects.

#### **Reverse causality analysis**

To clarify reverse causal associations from gut microbiota, immune cells, and inflammatory factors to neuropathic pain, we performed a reverse MR analysis with neuropathic pain as the exposure, and gut microbiota, immune cells, or inflammatory factors as the outcome. IVs were identified as SNPs significantly associated with neuropathic pain ( $P < 5 \times 10^{-6}$ ).

We performed all analyses using R software (V.4.3.0) using the "TwoSampleMR" and "MRPRESSO" packages. We adopted the Bonferroni correction *P*-value as the threshold for statistical significance, which was  $6.84 \times 10^{-5}$  (0.05/731) and  $5.49 \times 10^{-4}$  (0.05/91) for immune cells and inflammatory factors, respectively. Any *P*-value of <0.05 but greater than the Bonferroni correction *P*-value threshold was considered a suggestive causal association.

# Results

### IV selection

After LD clumping and harmonization, we identified 3925 SNPs associated with gut microbiota ( $P < 1 \times 10^{-5}$ ) (Additional file 1: Table S2). Subsequently, 2018 and 283 SNPs associated with immune cells and inflammatory factors were selected, respectively ( $P < 5 \times 10^{-8}$ ) (Additional file 1: Table S3 and S4), with F-statistics exceeding 10, indicating a strong representation of neuropathic pain in the MR analysis.

# Causal effects of gut microbiota, immune cells, and inflammatory factors on neuropathic pain

We performed a two-sample MR analysis between gut microbiota and the five neuropathic pain subtypes. Based on IVW method estimates with P<0.05 and consistent effect directions across all six methods, we finally identified 67 causal associations from gut microbiota to neuropathic pain [26 gut bacterial taxa (1 phylum, 1 class, 1 order, 4 families, 5 genera, and 14 species from p\_Actinobacteria, p\_Bacteroidetes, p\_Firmicutes, and p\_Proteobacteria) and 35 gut bacterial pathway abundances (GAPAs)] (Additional file 1: Table S5, Figs. 2 and 3). Subsequently, we identified 147 paired causal associations from immune cells to various forms of neuropathic pain, including 34, 23, 51, 10, and 29 for drug-induced neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, and unspecified neuralgia, respectively (Additional file 1: Table S6, Fig. 4). Additionally, we identified 17 paired causal associations from inflammatory factors to neuropathic pain (2, 1, 3, 4, and 7 for drug-induced neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, and unspecified neuralgia, respectively) (Additional file 1: Table S7, Fig. 5).

#### **Drug-induced neuropathy**

Four gut microbiota (g\_Dialister, s\_Dialister invisus, s\_Dorea unclassified, and s\_Ruminococcus obeum) and six gut bacterial pathway abundances (GBPAs) [adenine and adenosine salvage III, cinnamate and

Exposure	Outcome	nSNP	pval		OR (95% CI)
g_Dialister	drug-induced_neuropathy	6	0.005	· · · · · · · · · · · · · · · · · · ·	→ 2.485 (1.320 - 4.681)
s_Dialister_invisus	drug-induced_neuropathy	6	0.027	•	→ 2.059 (1.084 - 3.911)
s_Dorea_unclassified	drug-induced_neuropathy	10	0.004	<b>⊢</b> ⊷−1	0.556 (0.374 - 0.826)
s_Ruminococcus_obeum	drug-induced_neuropathy	13	0.032	·	→ 1.885 (1.058 - 3.361)
s_Desulfovibrio_piger	postherpetic_neuralgia	6	0.028	· · · · · · · · · · · · · · · · · · ·	1.715 (1.060 - 2.774)
s_Dorea_formicigenerans	postherpetic_neuralgia	1	0.002		→ 12.014 (2.514 - 57.406)
s_Eubacterium_hallii	postherpetic_neuralgia	11	0.003	<b></b>	0.543 (0.361 - 0.816)
s_Lachnospiraceae_bacterium_3_1_46FAA	postherpetic_neuralgia	4	0.027	<b></b>	0.520 (0.291 - 0.929)
s_Oxalobacter_formigenes	postherpetic_neuralgia	10	0.042	••	1.507 (1.015 - 2.238)
f_Oxalobacteraceae	postherpetic_neuralgia	10	0.042	· · · · · · · · · · · · · · · · · · ·	1.507 (1.016 - 2.237)
s_Alistipes_shahii	sciatica	11	0.023	H H	0.908 (0.835 - 0.987)
s_Coprococcus_comes	sciatica	9	0.029	H	0.925 (0.863 - 0.992)
g_Paraprevotella	sciatica	10	0.048	H	0.940 (0.884 - 0.999)
p_Proteobacteria	sciatica	10	0.035	н	0.919 (0.851 - 0.994)
s_Roseburia_hominis	sciatica	7	0.028	H-1	0.892 (0.806 - 0.988)
s_Bacteroides_plebeius	trigeminal_neuralgia	7	0.042	H++	0.854 (0.733 - 0.995)
f_Clostridiales_noname	trigeminal_neuralgia	8	0.041		1.294 (1.010 - 1.659)
c_Deltaproteobacteria	trigeminal_neuralgia	6	0.007	<b>F---1</b>	0.615 (0.432 - 0.875)
f_Desulfovibrionaceae	trigeminal_neuralgia	6	0.007	<b>F---1</b>	0.615 (0.432 - 0.875)
o_Desulfovibrionales	trigeminal_neuralgia	6	0.007	<b>F---1</b>	0.615 (0.432 - 0.875)
g_Eggerthella	trigeminal_neuralgia	5	0.031	<b>⊢</b> ⊷-4	0.803 (0.657 - 0.980)
s_Roseburia_unclassified	trigeminal_neuralgia	14	0.028	<b></b>	1.213 (1.021 - 1.440)
g_Ruminococcus	trigeminal_neuralgia	10	0.011	F++-1	0.711 (0.546 - 0.926)
c_Deltaproteobacteria	unspecified_neuralgia	6	0.020	► • • · · · · · · · · · · · · · · · · ·	0.638 (0.437 - 0.932)
f_Desulfovibrionaceae	unspecified_neuralgia	6	0.020	<b></b>	0.638 (0.437 - 0.932)
o_Desulfovibrionales	unspecified_neuralgia	6	0.020	<b>—</b>	0.638 (0.437 - 0.932)
s_Roseburia_unclassified	unspecified_neuralgia	14	0.019		1.202 (1.031 - 1.403)
g_Ruminococcaceae_noname	unspecified_neuralgia	10	0.049	++-	0.875 (0.767 - 1.000)
s_Ruminococcus_lactaris	unspecified_neuralgia	6	0.033	<b>⊢</b> ⊷(	0.750 (0.576 - 0.977)
f_Streptococcaceae	unspecified_neuralgia	14	0.045		0.842 (0.712 - 0.996)

Fig. 2 Mendelian randomization (MR) results of causal associations between gut microbiota and neuropathic pain. OR: odds ratio; CI: confidence interval. The prefix "p\_/c\_/o\_/f\_/g\_/s\_" represents phylum/class/order/family/genus/species, respectively

3-hydroxycinnamate degradation to 2-oxopent-4-enoate, creatinine degradation I, glycolysis I from glucose-6-phosphate, lipid IVA biosynthesis, and purine nucleotide degradation II (aerobic)] were causally associated with drug-induced neuropathy. The s\_Dorea unclassified (OR=0.556, 95% CI=0.374–0.826, P=0.004) and purine nucleotide degradation II (aerobic) (OR=0.415, 95% CI=0.216–0.798, P=0.008) were most significantly associated with a reduced risk of drug-induced neuropathy. Conversely, g\_Dialister (OR=2.485, 95% CI=1.320– 4.681, P=0.005) and adenine and adenosine salvage III (OR=2.433, 95% CI=1.238–4.779, P=0.010) were associated with an increased risk of drug-induced neuropathy.

Figure 4a showed that 23 types of immune cells were positively associated with the risk of drug-induced neuropathy, with natural killer T absolute count (OR=2.312, 95% CI=1.317-4.058, P=0.003) having the strongest

impact on drug-induced neuropathy. However, 11 types of immune cells were negatively associated with the risk of drug-induced neuropathy, with CD4+/CD8+T cell (OR=0.046, 95% CI=0.005-0.449, P=0.008) showing the most significant protective effect on drug-induced neuropathy. Moreover, interleukin-1-alpha (OR=10.034, 95% CI=1.945-51.753, P=0.006) and T-cell surface glycoprotein CD5 (OR=2.315, 95% CI=1.099-4.879, P=0.027) were significantly correlated with an increased risk of drug-induced neuropathy (Fig. 5).

#### Postherpetic neuralgia

Six gut microbiotas and eight GBPAs were causally associated with postherpetic neuralgia (Figs. 2 and 3). The most notable protective factors were s\_*Eubacterium hallii* (OR=0.543, 95% CI=0.361-0.816, P=0.003) and fucose degradation (OR=0.416, 95% CI=0.230-0.751,

Exposure	Outcome	nSNP	pval		OR (95% CI)
GBPA_Adenine and Adenosine Salvage III	drug-induced_neuropathy	14	0.010	· · · · · · · · · · · · · · · · · · ·	2.433 (1.238 - 4.779)
GBPA_Cinnamate and 3-Hydroxycinnamate Degradation to 2-Oxopent-4-enoate	drug-induced_neuropathy	8	0.036	<b>—</b>	0.563 (0.329 - 0.964)
GBPA_Creatinine Degradation I	drug-induced_neuropathy	8	0.043		0.543 (0.300 - 0.982)
GBPA_Glycolysis I from Glucose 6-Phosphate	drug-induced_neuropathy	15	0.027	· · · · · · · · · · · · · · · · · · ·	2.016 (1.081 - 3.761)
GBPA_Lipid IVA Biosynthesis	drug-induced_neuropathy	10	0.040	→ <b>→</b>	0.455 (0.215 - 0.966)
GBPA_Purine Nucleotides Degradation II (Aerobic)	drug-induced_neuropathy	14	0.008	<b>••••</b>	0.415 (0.216 - 0.798)
GBPA_Fucose Degradation	postherpetic_neuralgia	10	0.004	<b>→→→</b>	0.416 (0.230 - 0.751)
GBPA_Glycerol Degradation to Butanol	postherpetic_neuralgia	15	0.044	<b>→→→</b>	0.679 (0.466 - 0.990)
GBPA_Glycolysis I from Glucose 6-Phosphate	postherpetic_neuralgia	15	0.046		1.656 (1.009 - 2.717)
GBPA_L-Arginine Biosynthesis IV (Archaebacteria)	postherpetic_neuralgia	9	0.041		1.959 (1.028 - 3.732)
GBPA_L-Glutamate Degradation V (via Hydroxyglutarate)	postherpetic_neuralgia	11	0.033	· · · · · · · · · · · · · · · · · · ·	1.816 (1.048 - 3.145)
GBPA_L-Histidine Biosynthesis	postherpetic_neuralgia	10	0.013	•••••	0.493 (0.282 - 0.861)
GBPA_Phosphatidylglycerol Biosynthesis I (Plastidic)	postherpetic_neuralgia	17	0.004	· · · · · · · · · · · · · · · · · · ·	2.094 (1.268 - 3.456)
GBPA_Polyisoprenoid Biosynthesis (E. coli)	postherpetic_neuralgia	8	0.013		I.709 (1.121 − 2.607)
GBPA_6-Hydroxymethyl-Dihydropterin Diphosphate Biosynthesis I	sciatica	14	0.018	++(	0.898 (0.822 - 0.982)
GBPA_guanosine ribonucleotides de novo biosynthesis	sciatica	15	0.001	H	0.897 (0.840 - 0.959)
GBPA_inosine 5'-phosphate biosynthesis III	sciatica	10	0.009	H	0.892 (0.819 - 0.972)
GBPA_Superpathway of Purine Deoxyribonucleosides Degradation	sciatica	10	0.047	++	0.914 (0.836 - 0.999)
GBPA_TCA Cycle V (2-Oxoglutarate Ferredoxin Oxidoreductase)	sciatica	15	800.0	H	0.911 (0.850 - 0.975)
GBPA_TCA cycle VII (acetate producers)	sciatica	10	0.030	H	0.935 (0.880 - 0.993)
GBPA_Chorismate Biosynthesis I	trigeminal_neuralgia	13	0.024		1.315 (1.036 - 1.670)
GBPA_L-Lysine Biosynthesis VI	trigeminal_neuralgia	17	0.029		1.270 (1.025 - 1.574)
GBPA_Mannosylglycerate Biosynthesis I	trigeminal_neuralgia	10	0.024	⊷(	0.862 (0.758 - 0.981)
GBPA_Pyrimidine Deoxyribonucleotides De Novo Biosynthesis III	trigeminal_neuralgia	8	0.031	<b>→</b> →→	0.645 (0.432 - 0.962)
GBPA_Sulfate Reduction I Assimilatory	trigeminal_neuralgia	4	0.046	· · · · · · · · · · · · · · · · · · ·	1.531 (1.007 - 2.330)
GBPA_Superpathway of Acetyl-CoA Biosynthesis	trigeminal_neuralgia	12	0.007	<b></b>	1.329 (1.081 - 1.634)
GBPA_superpathway of GDP-Mannose Derived O-Antigen Biosynthesis	trigeminal_neuralgia	10	0.006	<b>→→→</b> }	0.677 (0.514 - 0.892)
GBPA_4-Aminobutanoate Degradation V	unspecified_neuralgia	5	0.021	<b>—</b>	0.586 (0.372 - 0.922)
GBPA_6-Hydroxymethyl-Dihydropterin Diphosphate Biosynthesis I	unspecified_neuralgia	14	0.026	·	1.323 (1.034 - 1.693)
GBPA_Aspartate Superpathway	unspecified_neuralgia	11	0.037	<b>→</b> →-(	0.743 (0.563 - 0.982)
GBPA_CDP-Diacylglycerol Biosynthesis I	unspecified_neuralgia	16	0.025	<b>⊢</b> ⊷{	0.759 (0.596 - 0.967)
GBPA_NAD Salvage Pathway I	unspecified_neuralgia	15	0.040	H++-	0.820 (0.679 - 0.991)
GBPA_Superpathway of Geranylgeranyl Diphosphate Biosynthesis II (via MEP)	unspecified_neuralgia	13	0.012	H+++	0.752 (0.602 - 0.940)
GBPA_Superpathway of Guanosine Nucleotides De Novo Biosynthesis II	unspecified_neuralgia	10	0.025	<b>⊷</b> ⊷	0.684 (0.490 - 0.954)
GBPA_Superpathway of Heme Biosynthesis from Uroporphyrinogen III	unspecified_neuralgia	9	0.006		1.310 (1.079 - 1.591)
GBPA_superpathway of L-arginine, putrescine, and 4-aminobutanoate degradation	unspecified_neuralgia	1	0.035	<b>⊢</b> ⊷–-(	0.690 (0.488 - 0.975)
GBPA_Urea Cycle	unspecified_neuralgia	8	0.016	<b>H</b>	0.661 (0.472 - 0.925)
			(	0 0.5 1 1.5 2 2.	5 3

Fig. 3 MR results of causal associations between gut bacterial pathway abundances (GBPAs) and neuropathic pain. OR: odds ratio; CI: confidence interval

P=0.004). However, the most significant risk factors were s\_*Dorea formicigenerans* (OR=12.014, 95% CI=2.514–57.406, P=0.002) and phosphatidylglycerol biosynthesis I (plastidic) (OR=2.094, 95% CI=1.268–3.456, P=0.004).

Five types of immune cells were positively associated with the incidence of postherpetic neuralgia, with CD45 on B cell (OR=3.165, 95% CI=1.403–7.142, P=0.006) having the strongest effect on postherpetic neuralgia (Fig. 4b). Conversely, 18 types of immune cells were negatively associated with the incidence of postherpetic neuralgia, with CD62L-plasmacytoid dendritic cell % dendritic cell (OR=0.504, 95% CI=0.326–0.779, P=0.002) having the strongest effect on postherpetic neuralgia. Additionally, adenosine deaminase (OR=0.675, 95% CI=0.484–0.941, P=0.020) acted as a protective factor against postherpetic neuralgia (Fig. 5).

# Sciatica

Notably, five gut microbiotas (s\_*Alistipes shahii*, s\_*Coprococcus comes*, g\_Paraprevotella, p\_Proteobacteria, and s\_*Roseburia hominis*) and six GBPAs [6-hydroxymethyl-dihydropterin diphosphate biosynthesis I, guanosine ribonucleotide de novo biosynthesis, inosine 5'-phosphate biosynthesis III, superpathway of purine deoxyribonucleoside degradation, TCA cycle V(2-oxoglutarate ferredoxin oxidoreductase), and TCA cycle VII (acetate producers)] were causally associated with decreased sciatica risk, with s\_*Alistipes shahii* (OR=0.908, 95% CI=0.835-0.987, P=0.023) and guanosine ribonucleotide de novo biosynthesis (OR=0.897, 95% CI=0.840-0.959, P=0.001) being the most significant.

Furthermore, 32 and 19 types of immune cells were positively and negatively associated with sciatica risk, respectively (Fig. 4d). Among these, PDL-1 on CD14+CD16-monocyte (OR=1.234, 95% CI=1.068-1.426, P=0.004) and HLA DR on CD14+monocyte (OR=0.948, 95% CI=0.925-0.973, P<0.001) were most significantly associated with increased and decreased sciatica risks, respectively. Moreover, we identified that interleukin-18 (OR=0.888, 95% CI=0.826-0.955, P=0.001) and latency-associated peptide transforming

a	Outcome: drug-induced_neuropathy

Exposure	nSNP	OR (95% CI)		pval
CCR2 on myeloid Dendritic Cell	3	1.623 (1.053 - 2.501)	· · · · · · · · · · · · · · · · · · ·	0.028
CD127 on CD8+ T cell	1	2.981 (1.071 - 8.299)		• 0.037
CD20 on IgD+ B cell	5	1.682 (1.035 - 2.734)	· · · · · · · · · · · · · · · · · · ·	0.036
CD20 on IgD+ CD38dim B cell	7	1.537 (1.029 - 2.296)	)	0.036
CD20 on naive-mature B cell	6	1.659 (1.037 - 2.652)	) — • — • — •	0.035
CD24+ CD27+ B cell Absolute Count	1	20.313 (1.749 - 235.896)		• 0.016
CD28 on CD39+ secreting CD4 regulatory T cell	2	1.573 (1.015 - 2.438)	)	0.043
CD3 on resting CD4 regulatory T cell	5	0.671 (0.471 - 0.958)		0.028
CD4 on CD39+ CD4+ T cell	7	1.415 (1.007 - 1.988)		0.046
CD4 on CD39+ secreting CD4 regulatory T cell	3	1.650 (1.024 - 2.659)		0.039
CD4+/CD8+ T cell	1	0.046 (0.005 - 0.449)		0.008
CD45 on HLA DR+ T cell	1	0.400 (0.189 - 0.843)	H	0.016
CD8 on CD39+ CD8+ T cell	5	1.775 (1.066 - 2.954)		0.027
CD8+ T cell %T cell	1	20.918 (2.198 - 199.052)	· · · · · · · · · · · · · · · · · · ·	• 0.008
HLA DR on HLA DR+ CD4+ T cell	1	4.270 (1.322 - 13.797)		• 0.015
HLA DR on HLA DR+ Natural Killer	6	1.858 (1.034 - 3.337)	· · · · · · · · · · · · · · · · · · ·	• 0.038
HLA DR on HLA DR+ T cell	1	2.715 (1.211 - 6.084)	· · · · · ·	0.015
HLA DR on monocyte	4	1.376 (1.065 - 1.777)	;	0.014
HLA DR+ CD4+ T cell %lymphocyte	2	0.475 (0.260 - 0.870)	+++	0.016
HLA DR+ CD4+ T cell %T cell	1	0.421 (0.196 - 0.902)		0.026
HLA DR+ CD4+ T cell Absolute Count	2	0.478 (0.254 - 0.898)		0.022
HLA DR+ CD8+ T cell %lymphocyte	2	0.571 (0.364 - 0.895)		0.015
HLA DR+ CD8+ T cell Absolute Count	3	0.587 (0.377 - 0.912)		0.018
HLA DR+ T cell Absolute Count	3	0.596 (0.388 - 0.916)		0.018
HLA DR+ T cell%lymphocyte	4	0.627 (0.425 - 0.923)		0.018
HLA DR++ monocyte %leukocyte	2	1.894 (1.096 - 3.274)		• 0.022
HLA DR++ monocyte %monocyte	4	1.754 (1.145 - 2.685)	· · · · · · · · · · · · · · · · · · ·	0.010
IgD- CD38- B cell Absolute Count	1	2.829 (1.083 - 7.394)		• 0.034
IgD+ CD24+ B cell Absolute Count	1	13.383 (1.619 - 110.649)		• 0.016
Memory B cell Absolute Count	1	18.980 (1.727 - 208.561)		• 0.016
Natural Killer T Absolute Count	5	2.312 (1.317 - 4.058)	· · · · · ·	• 0.003
SSC-A on HLA DR+ T cell	1	0.301 (0.113 - 0.800)	H	0.016
Unswitched memory B cell %B cell	1	3.715 (1.015 - 13.595)		- 0.047
Unswitched memory B cell Absolute Count	2	6.560 (1.426 - 30.179)		0.016
			0 0.5 1 1.5 2 2.5	3

#### Outcome: postherpetic\_neuralgia

b

с

nSNP	OR (95% CI)			pval
1	0.607 (0.404 - 0.911)	· · · · · ·		0.016
1	0.598 (0.393 - 0.909)			0.016
2	0.471 (0.291 - 0.762)			0.002
2	0.474 (0.294 - 0.764)			0.002
3	1.491 (1.027 - 2.164)			0.036
2	0.408 (0.214 - 0.779)			0.007
2	3.165 (1.403 - 7.142)		-	0.006
4	0.561 (0.324 - 0.971)	(		0.039
2	0.504 (0.326 - 0.779)			0.002
1	0.444 (0.253 - 0.781)	i		0.005
5	0.664 (0.443 - 0.995)			0.047
2	0.450 (0.270 - 0.749)			0.002
2	0.453 (0.273 - 0.751)			0.002
2	0.461 (0.213 - 0.998)	<b></b>		0.049
2	0.480 (0.231 - 0.996)	<b>—</b>		0.049
3	0.483 (0.239 - 0.976)	· · · · · ·		0.043
1	10.110 (1.154 - 88.571)			0.037
4	0.554 (0.310 - 0.988)			0.046
4	0.812 (0.661 - 0.997)			0.047
1	0.433 (0.229 - 0.820)	i		0.010
2	2.660 (1.033 - 6.850)	→		0.043
1	2.538 (1.046 - 6.160)	)		0.040
1	0.225 (0.068 - 0.748)	++		0.015
		0 0.5 1	1.5 2 2.5	3
	nSNP 1 1 1 2 2 3 3 2 2 4 4 2 1 1 5 2 2 2 4 4 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1	nSNP         OR (95% CI)           1         0.607 (0.404 - 0.911)           1         0.569 (0.393 - 0.069)           2         0.471 (0.291 - 0.762)           2         0.471 (0.294 - 0.764)           3         1.491 (1.027 - 2.164)           2         0.476 (0.294 - 0.776)           2         0.476 (1.032 - 1.122)           3         1.691 (1.032 - 0.771)           1         0.564 (0.325 - 0.771)           1         0.564 (0.325 - 0.771)           2         0.564 (0.325 - 0.771)           2         0.564 (0.232 - 0.751)           2         0.456 (0.270 - 0.749)           2         0.456 (0.270 - 0.749)           2         0.458 (0.271 - 0.749)           2         0.458 (0.271 - 0.749)           2         0.458 (0.271 - 0.749)           2         0.458 (0.271 - 0.749)           2         0.458 (0.271 - 0.749)           2         0.458 (0.271 - 0.749)           3         0.432 (0.270 - 0.749)           3         0.432 (0.270 - 0.749)           4         0.554 (0.31 - 0.988)           4         0.554 (0.31 - 0.988)           4         0.554 (0.33 - 6.550)           1         0.154 (0.33	nSNP         OR (95% CI)           1         0.687 (0.404 - 0.911)           1         0.589 (0.332 - 0.909)           2         0.471 (0.291 - 0.762)           2         0.471 (0.291 - 0.762)           3         1.491 (0.272 - 2.164)           2         0.474 (0.294 - 0.772)           2         0.474 (0.294 - 0.772)           2         0.474 (0.294 - 0.776)           2         0.468 (0.214 - 0.779)           2         3.166 (1.032 - 0.977)           4         0.561 (0.324 - 0.977)           1         0.414 (0.255 - 0.751)           1         0.414 (0.255 - 0.751)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           2         0.468 (0.270 - 0.749)           3         0.483 (0.270 - 0.749)           4         0.554 (0.103 - 0.980)           4         0.554 (0.31 - 0.980)           4         0.554 (0.31 - 0.980)           4         0.554 (0.31 - 0.880)           1         0.541 (0.46	nSNP         OR (95% CI)           1         0.607 (0.404 - 0.811)           1         0.568 (0.393 - 0.908)           2         0.474 (0.294 - 0.762)           2         0.474 (0.294 - 0.762)           3         1.401 (0.277 - 2.164)           2         0.468 (0.214 - 0.778)           2         0.468 (0.236 - 0.778)           2         0.468 (0.236 - 0.778)           4         0.551 (0.326 - 0.971)           1         0.446 (0.255 - 0.781)           2         0.648 (0.236 - 0.778)           2         0.468 (0.236 - 0.778)           4         0.551 (0.326 - 0.988)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.784)           2         0.468 (0.237 - 0.988)           4         0.554 (0.337 - 0.882)           2         2.660 (1.033 - 6.850)           1         0.433 (0.239 - 0.820)           2         2.660 (1.033 - 6.850)           1         2.353 (1.046 - 6.160)           1         0.252 (0.

#### Outcome: trigeminal\_neuralgia

Exposure	nSNP	OR (95% CI)		pva
CD11c on CD62L+ myeloid Dendritic Cell	2	1.254 (1.062 - 1.481)		0.00
CD19 on IgD+ B cell	2	0.624 (0.426 - 0.914)		0.01
CD19 on naive-mature B cell	2	0.474 (0.254 - 0.886)		0.01
CD20 on IgD- CD38- B cell	4	1.301 (1.015 - 1.669)		0.03
CD39+ CD4+ T cell Absolute Count	5	1.149 (1.008 - 1.310)		0.03
CD62L- plasmacytoid Dendritic Cell %Dendritic Cell	2	0.784 (0.639 - 0.963)		0.02
CD62L- plasmacytoid Dendritic Cell Absolute Count	1	0.738 (0.562 - 0.968)		0.02
HLA DR on CD33- HLA DR+	2	1.098 (1.006 - 1.199)		0.03
HLA DR on Dendritic Cell	7	1.079 (1.006 - 1.157)	-	0.03
Unswitched memory B cell %B cell	1	0.420 (0.245 - 0.722)	0 0.5 1 1.5 2	2.5 3

<b>d</b> Օւ	ıtcom	e: sciatica		
Exposure	nSNP	OR (95% CI)		pval
B cell %CD3- lymphocyte	3	0.955 (0.914 - 0.998)		0.039
CCR2 on CD14- CD16+ monocyte	1	1.182 (1.013 - 1.378)		0.034
CCR2 on myeloid Dendritic Cell	3	0.935 (0.892 - 0.980)		0.005
CD11c+ CD62L- monocyte Absolute Count	1	0.801 (0.670 - 0.958)	HH4	0.015
CD14- CD16- Absolute Count	3	1.115 (1.017 - 1.222)	→-	0.021
CD14- CD16+ monocyte Absolute Count	1	0.906 (0.827 - 0.993)	H	0.034
CD16-CD56 on HLA DR+ Natural Killer	2	1.190 (1.054 - 1.344)		0.005
CD24 on IgD+ CD38+ B cell	2	0.846 (0.756 - 0.948)	++4	0.004
CD24 on transitional B cell	1	0.845 (0.738 - 0.968)	H=4	0.01
CD25 on IgD- CD27- B cell	2	0.902 (0.829 - 0.982)	H	0.01
CD25++ CD8+ T cell %CD8+ T cell	1	1.077 (1.011 - 1.146)		0.02
CD28- CD127- CD25++ CD8+ T cell Absolute Count	1	0.832 (0.742 - 0.933)		0.00
CD3 on CD28+ CD4+ T cell	2	1.048 (1.006 - 1.092)	H	0.02
CD3 on CD28+ CD45RA- CD8+ T cell	5	1.057 (1.002 - 1.115)	-	0.04
CD3 on CD39+ activated CD4 regulatory T cell	5	1.034 (1.002 - 1.066)	+	0.03
CD3 on CD39+ CD8+ T cell	1	1.073 (1.005 = 1.146)	H-1	0.03
CD3 on CD39+ resting CD4 regulatory T cell	1	1.081 (1.008 - 1.160)	<b>⊢</b>	0.02
CD3 on CD8+ T cell	2	1.061 (1.009 - 1.116)	H.	0.02
CD3 on HLA DR+ CD8+ T cell	1	1.095 (1.009 - 1.188)	H-	0.03
CD3 on HLA DR+ T cell	2	1.057 (1.003 - 1.114)	H-	0.03
CD3 on T cell	3	1.044 (1.000 - 1.089)	H	0.05
CD3 on Terminally Differentiated CD4+ T cell	1	1.094 (1.006 - 1.190)	i an	0.03
CD39+ CD8+ T cell %CD8+ T cell	7	1.047 (1.005 - 1.090)	-	0.02
CD4 on naive CD4+ T cell	5	0.870 (0.791 - 0.956)	144	0.00
CD62L- Dendritic Cell %Dendritic Cell	4	1.053 (1.014 - 1.093)	-	0.00
CD80 on monocyte	6	0.967 (0.936 - 0.999)		0.04
CD86 on monocyte	1	0.870 (0.761 - 0.995)	H	0.04
CD86 on myeloid Dendritic Cell	1	1.075 (1.011 - 1.144)	in the second se	0.02
CD86+ plasmacytoid Dendritic Cell %Dendritic Cell	1	0.859 (0.763 - 0.968)	H	0.01
Dendritic Cell Absolute Count	3	1 060 (1 004 - 1 118)		0.03
HLA DR on CD14+ CD16- monocyte	5	0.950 (0.927 - 0.973)		<0.0
HIADB on CD14+ monocyte	5	0.948 (0.925 - 0.973)	4	<0.01
HI A DB+ Natural Killer %Natural Killer	6	0.958 (0.923 - 0.993)		0.01
HI & DB++ monocyte %leukocyte	2	0.892 (0.840 - 0.947)		<0.01
HI A DR++ monocyte Absolute Count	1	0.851 (0.780 - 0.928)	Hell	<0.0
HVEM on CD4+ T cell	1	1.085 (1.012 = 1.162)	and the second se	0.02
HVEM on CD45BA- CD4+ T cell	1	1.083 (1.012 - 1.158)		0.02
HVEM on CD8+ T cell	1	1.085 (1.003 = 1.173)		0.04
HVEM on Central Memory CD4+ T cell	1	1.087 (1.013 - 1.167)		0.04
HVEM on Central Memory CD8+ T cell	1	1.080 (1.012 - 1.153)	her	0.02
HVEM on Effector Memory CD4+ T cell	1	1.006 (1.022 - 1.176)	- C	0.01
HVEN on Effector Memory CD9+ T cell	4	1.097 (1.012 - 1.167)	C	0.01
HVEM on pairs CD4+ T coll	1	1.007 (1.013 - 1.107)	C	0.02
HVEN on T coll	-	1.034 (1.000 1.100)		0.03
UVEN on Terminally Differentiated OD4+ T cell	4	1.007 (1.013 - 1.100)	C	0.02
Independent of the second seco	2	0.001 (0.069 - 0.007)		0.04
Nucleid Departitie Call Absolute Count	2	0.521 (0.000 - 0.987)		0.02
Naive CD4-CD8- T cell %T cc"	3	1.000 (1.000 - 1.101)		0.04
maive CD4=CD6= 1 cell % 1 cell		1.103 (1.000 = 1.351)		0.04
Put-1 on CD14+ CD16- monocyte	1	1.234 (1.068 - 1.426)		0.00
masmacytolo Denontic Cell %Denontic Cell	2	0.900 (0.903 - 0.998)		0.04
SSC-A on lymphocyte	1	1.182 (1.048 - 1.333)		1
			0 0.0 T 1.0 Z Z.0	5
e Outcome:	unsp	ecified_neur	algia	

	outcome.	unspecifi	ieu_neuruigiu	
_				

Exposure	nSNP	OR (95% CI)		pval
CD127- CD8+ T cell Absolute Count	1	1.624 (1.121 - 2.353)	;	0.010
CD25 on CD4+ T cell	1	1.648 (1.037 - 2.618)	)	0.035
CD25 on CD45RA- CD4 not regulatory T cell	2	1.337 (1.016 - 1.758)	→ <b>→</b> →	0.038
CD25++ CD4+ T cell %CD4+ T cell	2	1.365 (1.038 - 1.795)	)	0.026
CD25++ CD4+ T cell %T cell	1	1.453 (1.027 - 2.055)		0.035
CD25++ CD4+ T cell Absolute Count	1	1.517 (1.031 - 2.233)		0.035
CD25++ CD45RA- CD4 not regulatory T cell Absolute Count	2	1.260 (1.006 - 1.578)		0.044
CD25++ CD8+ T cell Absolute Count	3	1.240 (1.023 - 1.503)		0.029
CD3 on Natural Killer T	2	0.667 (0.454 - 0.980)	<b></b>	0.039
CD33+ HLA DR+ CD14dim %CD33+ HLA DR+	1	1.446 (1.058 - 1.977)		0.021
CD4 on HLA DR+ CD4+ T cell	2	1.564 (1.150 - 2.128)		0.004
CD4 on monocyte	1	0.708 (0.516 - 0.973)	<b>→→</b> <	0.033
CD4 regulatory T cell %T cell	1	2.519 (1.348 = 4.705)	· · · · · · · · · · · · · · · · · · ·	0.004
CD45 on Immature Myeloid=Derived Suppressor Cells	2	1.139 (1.003 = 1.293)	<b>⊢</b> ⊷	0.044
CD8+ T cell %leukocyte	1	1.671 (1.129 - 2.473)	· · · · · · · · · · · · · · · · · · ·	0.010
CD8+ T cell Absolute Count	1	1.632 (1.122 - 2.373)		0.010
CD8dim T cell %leukocyte	2	0.675 (0.464 - 0.982)		0.040
CD8dim T cell %T cell	2	0.691 (0.485 - 0.986)		0.041
CD8dim T cell Absolute Count	3	0.698 (0.496 - 0.983)	H	0.039
FSC-A on plasmacytoid Dendritic Cell	4	0.733 (0.556 - 0.966)		0.028
HLA DR on CD33dim HLA DR+ CD11b-	5	1.139 (1.027 - 1.264)		0.013
IgD- CD38dim B cell %lymphocyte	2	0.647 (0.438 - 0.956)		0.029
Immature Myeloid-Derived Suppressor Cells Absolute Count	2	0.838 (0.716 - 0.982)		0.029
Memory B cell %lymphocyte	2	0.571 (0.361 - 0.902)		0.016
Naive CD4-CD8- T cell %T cell	1	0.528 (0.310 - 0.899)		0.019
Naive CD8+ T cell %CD8+ T cell	1	2.018 (1.019 - 3.995)	→	0.044
Plasma Blast-Plasma Cell %lymphocyte	1	1.807 (1.042 - 3.132)	)	0.035
SSC-A on Natural Killer T	2	0.610 (0.421 - 0.883)		0.009
T/B cell	2	1.707 (1.131 - 2.576)		0.011
			0 05 1 15 0 05 0	

Fig. 4 MR results of causal associations between immune cells and neuropathic pain. The results are presented for (a) drug-induced neuropathy, (b) postherpetic neuralgia, (c) trigeminal neuralgia, (d) sciatica, and (e) unspecified neuralgia. OR: odds ratio; CI: confidence interval

growth factor beta 1 (OR=0.900, 95% CI=0.815–0.994, P=0.038) were significantly associated with reduced sciatica risk (Fig. 5), but stem cell factor (KITLG) (OR=1.706, 95% CI=1.006–1.152, P=0.034) significantly increased sciatica risk.

## **Trigeminal neuralgia**

Eight gut microbiotas and seven GBPAs were associated with trigeminal neuralgia (Figs. 2 and 3). The most notable were c\_Deltaproteobacteria, o\_Desulfovibrionales, f\_Desulfovibrionaceae (OR=0.615, 95% CI=0.432-0.875, P=0.007), and superpathway of GDP-mannose-derived o-antigen biosynthesis (OR=0.677, 95% CI=0.514-0.892, P=0.006). However, s\_Roseburia unclassified (OR=1.213,

Exposure	Outcome	nSNP	OR (95% CI)		pval
Interleukin-1-alpha levels	drug-induced_neuropathy	1	10.034 (1.945 - 51.753)		• 0.006
T-cell surface glycoprotein CD5 levels	drug-induced_neuropathy	6	2.315 (1.099 - 4.879)	·	• 0.027
Adenosine Deaminase levels	postherpetic_neuralgia	3	0.675 (0.484 - 0.941)	H	0.020
Interleukin-18 levels	sciatica	4	0.888 (0.826 - 0.955)	He l	0.001
Latency-associated peptide transforming growth factor beta 1 levels	sciatica	2	0.900 (0.815 - 0.994)	H-H	0.038
Stem cell factor levels	sciatica	11	1.076 (1.006 - 1.152)	H.	0.034
Interleukin-15 receptor subunit alpha levels	trigeminal_neuralgia	3	0.821 (0.700 - 0.962)	H	0.015
SIR2-like protein 2 levels	trigeminal_neuralgia	1	2.060 (1.115 - 3.805)	· · · · · · · · · · · · · · · · · · ·	• 0.021
TNF-beta levels	trigeminal_neuralgia	5	0.860 (0.758 - 0.976)	H=4	0.019
Tumor necrosis factor ligand superfamily member 14 levels	trigeminal_neuralgia	4	1.322 (1.036 - 1.687)		0.025
C-X-C motif chemokine 10 levels	unspecified_neuralgia	5	1.413 (1.036 - 1.928)	· · · · · · · · · · · · · · · · · · ·	0.029
Eukaryotic translation initiation factor 4E-binding protein 1 levels	unspecified_neuralgia	2	0.620 (0.389 - 0.988)	<b>•••</b> ••	0.045
Latency-associated peptide transforming growth factor beta 1 levels	unspecified_neuralgia	2	0.647 (0.455 - 0.921)	•••••	0.016
Natural killer cell receptor 2B4 levels	unspecified_neuralgia	6	1.714 (1.327 - 2.215)	► <b>•</b> • • • •	<0.001
Neurotrophin-3 levels	unspecified_neuralgia	1	0.225 (0.090 - 0.559)	++	0.001
TNF-related apoptosis-inducing ligand levels	unspecified_neuralgia	9	1.244 (1.061 - 1.458)		0.007
Tumor necrosis factor ligand superfamily member 12 levels	unspecified_neuralgia	6	0.710 (0.529 - 0.953)	<b>H</b>	0.023
				0 0.5 1 1.5 2 2.5	3

Fig. 5 MR results of causal associations between inflammatory proteins and neuropathic pain

95% CI=1.021–1.440, P=0.028) and the superpathway of acetyl-CoA biosynthesis (OR=1.329, 95% CI=1.081–1.634, P=0.007) were strongly associated with increased trigeminal neuralgia risk.

Five types of immune cells were positively associated with trigeminal neuralgia risk (Fig. 4c). Notably, CD11c on CD62L+myeloid dendritic cell (OR=1.254, 95% CI=1.062-1.481, P=0.007) showed the strongest effect. Conversely, another five types of immune cells were negatively associated with trigeminal neuralgia risk, with unswitched memory B cell % B cell (OR=0.420, 95% CI=0.245-0.722, P=0.002) being the most significant. Moreover, interleukin-15 receptor subunit alpha (OR=0.821, 95% CI=0.700-0.962, P=0.015) and TNFbeta (OR=0.860, 95% CI=0.758-0.976, P=0.019) were significantly correlated with decreased trigeminal neuralgia risk (Fig. 5). However, SIR2-like protein 2 (OR=2.060, 95% CI=1.115-3.805, P=0.021) and tumor necrosis factor ligand superfamily member 14 (OR=1.322, 95% CI=1.036-1.687, P=0.025) significantly increased trigeminal neuralgia risk (Fig. 5).

## Unspecified neuralgia

Seven gut microbiotas were significantly associated with unspecified neuralgia (Figs. 2 and 3). As protective factors, the c\_Deltaproteobacteria, o\_Desulfovibrionales, and f\_Desulfovibrionaceae (OR=0.638, 95% CI=0.437–0.932, P=0.020) showed the strongest associations. However, only s\_Roseburia unclassified (OR=1.202, 95% CI=1.031–1.403, P=0.019) was identified as a risk factor. Additionally, 10 GBPAs had causal associations with unspecified neuralgia, with the superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)

(OR=0.752, 95% CI=0.602–0.940, P=0.012) being the most significantly associated with reduced unspecified neuralgia risk. Conversely, the superpathway of heme biosynthesis from uroporphyrinogen III (OR=1.310, 95% CI=1.079–1.591, P=0.006) was the most significantly associated with increased unspecified neuralgia risk.

We identified 18 and 11 types of immune cells that significantly increased and reduced unspecified neuralgia risk, respectively (Fig. 4e). Among these, CD4 regulatory T cell % T cell (OR=2.519, 95% CI=1.348-4.705, P=0.004) was identified as the most notable risk factor, whereas SSC-A on natural killer T (OR=0.610, 95% CI=0.421-0.883, P=0.009) was the most significant protective factor. Furthermore, neurotrophin-3 (OR=0.225, 95% CI=0.090-0.559, P=0.001) was strongly associated with decreased unspecified neuralgia risk. Conversely, the natural killer cell receptor 2B4 (OR=1.714, 95% CI=1.327-2.215, P<0.001) was most significantly associated with increased unspecified neuralgia risk (Fig. 5).

### Sensitivity analysis

In sensitivity analysis, Cochran's Q test indicated no significant evidence of heterogeneity for the associations between gut microbiota and neuropathic pain and between inflammatory factors and neuropathic pain (P>0.05, Additional file 1: Table S8 and S10). However, heterogeneity was detected for HLA-DR on HLA-DR+natural killer cells, HLA-DR on monocytes, and CD4 on naive CD4+T cells (P>0.05, Additional file 1: Table S9). To ensure robust and reliable results, we used the IVW random effects model between the three immune cells and neuropathic pain. MR-Egger intercept and MR-PRESSO global test showed no pleiotropy

(P>0.05, Additional file 1: Table S8-S10). Furthermore, the leave-one-out analysis showed that no individual SNP significantly affected the causal relationship between gut microbiota and neuropathic pain (Additional file 2: Fig. S1-S5). Additionally, beyond the associations between GBPA-sulfate reduction I (assimilatory) and trigeminal neuralgia; g\_Paraprevotella and sciatica; g\_Ruminococcaceae noname and unspecified neuralgia; CD8dim T cell % leukocyte, CD8dim T cell % T cell, and memory B cell % lymphocyte and postherpetic neuralgia; and CD3 on T cell and sciatica, all other causal relationships were validated by at least one of the debiased IVW or RAPS methods, confirming the robustness of the results. For significant associations in the forward analysis, the reverse MR analysis showed no obvious causal effect of neuropathic pain on gut microbiotas, immune cells, and inflammatory factors (Additional file 1: Table S11–S13).

#### **Mediation analysis**

We explored the causal effects of neuropathic painrelated gut microbiota on immune cells and inflammatory factors associated with neuropathic pain (Additional file 1: Table S14). Based on the screening criteria, we preliminarily identified 21 potential gut microbiota-immune cells/inflammatory factor-neuropathic pain pathways (Additional file 1: Table S15). Finally, we identified that HLA-DR++monocyte % leukocyte mediated the causal pathway between p\_Proteobacteria and sciatica (OR=0.970, 95% CI=0.942-0.999, P=0.038), accounting for 36.15% of the total effect. In addition, CD11c on CD62L+myeloid dendritic cells might act as a mediator in the causal association between GBPA-sulfate reduction I (assimilatory) and trigeminal neuralgia (OR=1.126, 95% CI=1.002-1.266, P=0.041), with a mediation proportion of 27.90% (Fig. 6, Additional file 1: Table S16).

# Discussion

We used a bidirectional two-sample MR analysis to explore the causal relationships between gut microbiota and neuropathic pain, which showed 30 causal associations with genetic predispositions between 26 gut bacterial taxa and five types of neuropathic pain. Additionally, we discovered 37 causal relationships that involved 35 GBPAs associated with neuropathic pain. Some gut microbiota species and GBPAs were risk factors, whereas others were protective factors against various types of neuropathic pain. However, reverse MR analysis did not show significant causal associations from neuropathic pain to gut microbiota. Furthermore, our findings primarily focused on the mediation roles of immune cells in the relationship between gut microbiota and neuropathic pain. Our results indicated that immune cell phenotypes HLA-DR++monocyte % leukocyte mediated the causal relationship between p\_Proteobacteria and sciatica, whereas CD11c on CD62L+myeloid dendritic cells mediated the causal pathway from GBPAsulfate reduction I (assimilatory) on trigeminal neuralgia.

We identified several bacterial taxa from the phyla Firmicutes and Proteobacteria as protective factors for neuropathic pain. Jiao et al. revealed decreased abundances of f\_Lachnospiraceae, g\_Dorea, and s\_Eubacterium hallii, from the phylum Firmicutes, in patients with postherpetic neuralgia compared with healthy controls [39]. Similarly, the abundances of g Roseburia and s\_Coprococcus\_comes were decreased in patients with chronic pain [40, 41]. Additionally, these two taxa had reduced abundances in inflammatory diseases [42-44]. Jalanka-Tuovinen et al. reported a significant decrease in one phylotype within the Ruminococcus lactaris and related species group in patients with abdominal pain [45]. These findings support the hypothesis that these bacterial taxa play a protective role in neuropathic pain. For the phylum Proteobacteria, comprising c\_Deltaproteobacteria, o\_Desulfovibrionales, and f\_Desulfovibrionaceae, a recent study indicated that the abundances of these bacterial taxa were negatively associated with the severity of kidney injury in antineutrophil cytoplasmic antibody-associated vasculitis [46], indicating their protective roles. However, o Desulfovibrionales and f\_Desulfovibrionaceae, which reduce sulfate to  $H_2S_1$ , can damage the intestinal barrier, resulting in the production of endotoxins and pro-inflammatory cytokines [47]. This



Fig. 6 The results of mediation analysis. OR: odds ratio; CI: confidence interval. The prefix "p\_" represents phylum

appears contradictory, highlighting the possibility that these bacterial taxa may exert different regulatory roles across different diseases. Further studies are necessary to elucidate the regulatory mechanisms of phylum Proteobacteria and its subordinate bacterial taxa in neuropathic pain.

In terms of risk factors, our study indicated that the high abundances of s\_Dialister invisus from the genus Dialister, s\_Ruminococcus obeum from the genus Blautia, s\_Dorea formicigenerans from the genus Dorea, s\_Desulfovibrio piger from the genus Desulfovibrio, and s\_Roseburia unclassified from genus Roseburia were associated with an increased neuropathic pain risk. However, direct evidence regarding whether these specific strains influence neuropathic pain is limited. It was reported that the genus *Dialister* was significantly involved in chronic pain [48]. The relative increases in the ratios of Blautia to Lachnospira might be associated with distal neuropathic pain in HIV patients, suggesting the hypothesis that the genus Blautia could potentially contribute to the risk of neuropathic pain [49]. This hypothesis was further supported by Hadizadeh et al., who found that the abundance of the genus Blautia was increased in patients with abdominal pain [50]. Moreover, previous studies showed that a high abundance of s\_Dorea formicigenerans was associated with psoriasis and severe acute pancreatitis [51, 52]. In a recent study, the abundance of the genus Desulfovibrio was reduced in the treatment group of rats with spinal nerve ligation receiving ginger root extract, which alleviated pain [53]. Additionally, Goudman et al. reported an increased abundance of the genus *Roseburia* in patients with fibromyalgia [54]. These studies provide substantial clues that support our findings that these strains might be associated with increased neuropathic pain risk.

Additionally, our analysis revealed that some gut microbiota metabolic pathways were causally associated with neuropathic pain. Gut microbial metabolites, produced by metabolic pathways, are considered primary mediators through which the gut microbiota impact host physiology. These microbial metabolites play a significant role in regulating various chronic pain conditions such as headache, inflammatory pain, and neuropathic pain [55]. Studies have shown that the mechanisms involved in neuropathic pain are mediated by the activation of certain receptors or ion channels such as Toll-like receptors (TLRs) and transient receptor potential (TRP) channels [1]. Polyunsaturated fatty acids (PUFAs), as endogenous agonists of TRPV4, could stimulate sensory neurons to increase peripheral hypersensitivity, contributing to the development of neuropathic pain [1, 56]. However, acetyl-coenzyme A (CoA) is an essential precursor in de novo biosynthesis of fatty acids [57]. Therefore, we hypothesize that the superpathway of acetyl-CoA

biosynthesis may increase the risk of trigeminal neuralgia through a mechanism involving the activation of the TRPV4 channel driven by an increase in PUFAs. In addition, Diogenes et al. reported that lipopolysaccharide (LPS) might contribute to neuropathic pain by triggering TRPV1-mediated capsaicin responses via the TLR4 pathway [58]. Moreover, LPS could induce depolarization and firing of nociceptive neurons by activating the TRPA1 channel in a TLR4-independent manner, thereby leading to neurogenic inflammation and pain [1, 59]. These findings may provide plausible explanations for how s\_*Desulfovibrio piger*, a Gram-negative bacterium that produces LPS, increases the risk of postherpetic neuralgia in our study. However, the exact regulatory mechanisms remain to be further validated.

Acknowledging the close pathological relationships among various neuropathic pain, we further explored the shared gut microbiota and metabolic pathways causally associated with these disorders. Interestingly, our study identified specific species within the genus Roseburia linked to sciatica, trigeminal neuralgia, and unspecified neuralgia, while species from the genus Dorea were associated with drug-induced neuropathy and postherpetic neuralgia. Both genera belong to the family Lachnospiraceae, which has been found to have decreased abundance in chronic pain [41]. This evidence suggests that Lachnospiraceae may play a critical role in shared pathogenesis of various types of neuropathic pain. Additionally, we found that 6-hydroxymethyl dihydropterin diphosphate biosynthesis I was involved in sciatica and unspecified neuralgia, while glycolysis I from glucose-6-phosphate was causally associated with drug-induced neuropathy and postherpetic neuralgia.

To better understand the mechanisms by which gut microbiota affect neuropathic pain, we further focus on the pivotal roles of immune cells as mediators. Our study showed that different subtypes of dendritic cells such as myeloid and plasmacytoid dendritic cells, along with various subtypes of T cell, including CD4+T cells, CD8+T cells and regulatory T cells (Tregs), were causally associated with neuropathic pain. Dendritic cells recognized invading microbes through TLRs, triggering proinflammatory cytokine production and promoting antigen presentation to T cells, thereby activating adaptive immune responses [60]. Numerous studies have indicated that CD4+T helper 1 cells might contribute to the development and maintenance of pain, whereas CD8+T cells and Tregs could alleviate pain [12, 61, 62]. Subsequently, the mediation analysis revealed that the immune cell phenotype HLA-DR++monocyte % leukocyte mediated the causal effect of p\_Proteobacteria on sciatica. The monocyte expression of HLA-DR is crucial for presenting antigens to CD4+T cells, thereby initiating a specific immune response [63]. Monocytes/macrophages exerted analgesic effects by releasing anti-inflammatory mediators, such as IL-10 and specialized pro-resolving mediators, promoting the resolution of the initial injury [64, 65]. Furthermore, the absence of these cells impeded the resolution of inflammatory pain [66]. These findings supported that p\_Proteobacteria might decrease sciatica risk by regulating the anti-inflammatory effects mediated by HLA-DR++monocytes. Moreover, the immune cell phenotype CD11c on CD62L+myeloid dendritic cells mediated the effect of GBPA-sulfate reduction I (assimilatory) on trigeminal neuralgia. CD11c on CD62L+myeloid dendritic cell represents the expression of myeloid dendritic cells in peripheral blood. Dendritic cells contribute to cancer-associated neuropathic pain by sensitizing nociceptor sensory neurons through paracrine factors [67]. Assimilatory sulfate reduction in bacterial cells could produce cysteine, a precursor to glutathione crucial for maintaining redox homeostasis [68]. Glutathione deficiency inhibited dendritic cell maturation and reduced pro-inflammatory cytokine production [69, 70]. Thus, we deduced that assimilatory sulfate reduction increased trigeminal neuralgia risk by promoting dendritic cell maturation and subsequent pro-inflammatory cytokine production. Although we were unable to determine the mediating effect of certain immune cells and inflammatory factors, our findings offer potential insights into their mediation roles in the pathways from gut microbiota to neuropathic pain, warranting further research.

A recent study by Lan et al. revealed that several immune cells might mediate the effects of gut microbiota on neuropathic pain (trigeminal neuralgia, postherpetic neuralgia, and painful diabetic peripheral neuropathy) [26]. Compared with this recent study, there were some similarities and differences in our analysis. For data sources, we utilized the exact same version of the Finn-Gen R10 dataset as in Lan et al.'s study in the analysis of trigeminal neuralgia. However, we included a newer dataset for postherpetic neuralgia from FinnGen R10, compared to FinnGen R9 dataset in Lan et al.'s study. Moreover, we expanded our analysis to cover three additional types: drug-induced neuropathy, sciatica, and unspecified neuralgia. These datasets in our study included more samples, providing a more comprehensive and accurate analysis. Regarding methodology, our study has several differences: First, we similarly relaxed the *P*-value threshold for screening IVs of the gut microbiota from  $5 \times 10^{-8}$  to  $1 \times 10^{-5}$  in our study, potentially introducing weak IVs. Lan et al. conducted Bayesian weighted MR analysis as a supplementary analysis, whereas we implemented debiased IVW and RAPS as supplementary methods to reduce weak instrument bias. However, we maintained a strict threshold of  $P < 5 \times 10^{-8}$  for selecting more effective IVs for immune cells and inflammatory factors. Second, we used the F-statistic calculated from R<sup>2</sup> to provide a more accurate and comprehensive assessment of the genetic variance explained by the IVs, accounting for their correlation and minimizing the impact of multicollinearity. Third, only results with consistent effect directions across all methods were included in our analysis, ensuring the robustness and reliability of our findings. These differences in dataset versions and methodologies might contribute to the discrepancies in the IVs utilized for MR analysis, potentially leading to the differences between our findings and those reported by Lan et al. Furthermore, in addition to determining the mediating role of immune cells in the relationship between gut microbiota and neuropathic pain, we evaluated the potential mediating role of inflammatory factors, thereby enriching our understanding of the underlying mechanisms involved in neuropathic pain.

However, our study has certain limitations. The data in this study primarily come from individuals of European ancestry, potentially limiting the generalizability of our findings. Furthermore, we assumed a linear relationship between exposure and outcome in MR analyses, which may not capture the potentially more complex and nonlinear relationships. Moreover, we ensured consistent effect directions across all methods and applied a strict p-value threshold to select IVs for immune cells and inflammatory factors, enhancing the robustness of our results. However, these rigorous approaches may have inadvertently obscured the observation of some interesting findings. Additionally, due to the lack of individual-level data (such as details on the use of antibiotics, immunosuppressants, or other interventions), we were unable to perform subgroup analysis, potentially introducing some bias into our results. Finally, our results may be at risk for false positives without correction for multiple tests, and this study was intended to generate new hypotheses rather than final definitive conclusions. Thus, our findings should be considered preliminary and warrant further validation in future research.

#### Conclusion

In this study, we comprehensively explored the relationships between gut microbiota, immune cells, inflammatory factors, and neuropathic pain. There were 67 causal associations with genetic predispositions between gut microbiota (26 gut bacterial taxa and 35 GBPAs) and neuropathic pain. Additionally, immune cells may act as potential mediators in the causal pathways from gut microbiota to neuropathic pain, whereas inflammatory factors seem not to play a mediating role. These findings may provide novel insights into the pathogenesis and treatment strategies for neuropathic pain.

#### Abbreviations

SNI	Spared nerve injury
CCI	Chronic constriction injury

SCFAs	Short-chain fatty acids
MR	Mendelian randomization
SNPs	Single nucleotide polymorphisms
IVs	Instrumental variables
STROBE-MR	Strengthening the Reporting of Observational Studies in
	Epidemiology Mendelian Randomization
GWAS	Genome-wide association study
pQTL	Plasma protein quantitative trait loci
LD	Linkage disequilibrium
IVW	Inverse variance weighted
RAPS	Robust adjusted profile score
GAPAs	Gut bacterial pathway abundances
TLRs	Toll-like receptors
TRP	Transient receptor potential
PUFAs	Polyunsaturated fatty acids
CoA	Coenzyme A
LPS	Lipopolysaccharide
Tregs	Regulatory T cells

# **Supplementary Information**

The online version contains supplementary material available at https://doi.or g/10.1186/s10194-024-01906-z.

Supplementary Material 1

Supplementary Material 2

#### Acknowledgements

We extend our gratitude to all participants and researchers involved in the included GWAS studies for their invaluable contributions to the GWAS data.

#### Author contributions

H.P. and G.F.Z. jointly conceived and designed the study. H.P. and C.X.L. conducted data analysis and interpretation of results. H.P. and H.J.Z. created and optimized the visualizations. H.P. and G.F.Z. collaboratively wrote, revised, and edited the manuscript. All authors have read and approved the final version.

#### Funding

This work was in part supported by the following grands from the Natural Science Foundation of Shandong Province (ZR2022MH216 to GFZ) and the National Natural Science Foundation of China (No. 82371279 to GFZ).

#### Data availability

The GWAS summary statistics in this study are sourced from publicly open access databases including FinnGen (https://www.finngen.fi/en), IEU Open GWAS (https://gwas.mrcieu.ac.uk/), and GWAS Catalog (https://www.ebi.ac.uk /gwas/). Detailed information about the data used in the analyses is provided in the supplementary information files. Statistical code and additional information can be requested from the corresponding author.

#### Declarations

#### Ethics approval and consent to participate

Ethical approval was not applicable because this study used data from publicly available databases.

#### **Consent for publication**

Not application.

#### Competing interests

The authors declare no competing interests.

# Received: 18 July 2024 / Accepted: 6 November 2024 Published online: 11 November 2024

#### References

- Lin B, Wang Y, Zhang P, Yuan Y, Zhang Y, Chen G (2020) Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy. J Headache Pain 21:103
- Finnerup NB, Kuner R, Jensen TS (2021) Neuropathic Pain: from mechanisms to treatment. Physiol Rev 101:259–301
- Lehmann HC, Wunderlich G, Fink GR, Sommer C (2020) Diagnosis of peripheral neuropathy. Neurol Res Pract 2:20
- Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, Miggiano GAD, Gasbarrini A, Mele MC (2019) Food Components and Dietary habits: Keys for a healthy gut microbiota composition. Nutrients 11
- Corriero A, Gadaleta RM, Puntillo F, Inchingolo F, Moschetta A, Brienza N (2022) The central role of the gut in intensive care. Crit Care 26:379
- Chen P, Wang C, Ren YN, Ye ZJ, Jiang C, Wu ZB (2021) Alterations in the gut microbiota and metabolite profiles in the context of neuropathic pain. Mol Brain 14:50
- Yang C, Fang X, Zhan G, Huang N, Li S, Bi J, Jiang R, Yang L, Miao L, Zhu B et al (2019) Key role of gut microbiota in anhedonia-like phenotype in rodents with neuropathic pain. Transl Psychiatry 9:57
- Ma P, Mo R, Liao H, Qiu C, Wu G, Yang C, Zhang Y, Zhao Y, Song XJ (2022) Gut microbiota depletion by antibiotics ameliorates somatic neuropathic pain induced by nerve injury, chemotherapy, and diabetes in mice. J Neuroinflammation 19:169
- Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X (2019) Association between Peripheral Neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol 76:827–833
- 10. Kamada N, Seo SU, Chen GY, Núñez G (2013) Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 13:321–335
- 11. Jiang BC, Liu T, Gao YJ (2020) Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential. Pharmacol Ther 212:107581
- 12. Bethea JR, Fischer R (2021) Role of Peripheral Immune cells for Development and Recovery of Chronic Pain. Front Immunol 12:641588
- Shao X, Sun S, Zhou Y, Wang H, Yu Y, Hu T, Yao Y, Zhou C (2021) Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis. Cancer Lett 523:170–181
- Yu X, Liu H, Hamel KA, Morvan MG, Yu S, Leff J, Guan Z, Braz JM, Basbaum Al (2020) Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain. Nat Commun 11:264
- Ding W, You Z, Chen Q, Yang L, Doheny J, Zhou X, Li N, Wang S, Hu K, Chen L et al (2021) Gut Microbiota influences Neuropathic Pain through modulating Proinflammatory and anti-inflammatory T cells. Anesth Analg 132:1146–1155
- Sekula P, Del Greco MF, Pattaro C, Köttgen A (2016) Mendelian randomization as an Approach to assess causality using Observational Data. J Am Soc Nephrol 27:3253–3265
- Beeghly-Fadiel A, Khankari NK, Delahanty RJ, Shu XO, Lu Y, Schmidt MK, Bolla MK, Michailidou K, Wang Q, Dennis J et al (2020) A mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int J Epidemiol 49:1117–1131
- Tian D, Zhang L, Zhuang Z, Huang T, Fan D (2022) A two-sample mendelian randomization analysis of modifiable risk factors and intracranial aneurysms. Sci Rep 12:7659
- Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N et al (2021) Strengthening the reporting of Observational studies in Epidemiology using mendelian randomization: the STROBE-MR Statement. JAMA 326:1614–1621
- Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, Vander-Weele TJ, Timpson NJ, Higgins JPT, Dimou N, Langenberg C et al (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 375:n2233
- 21. Bowden J, Holmes MV (2019) Meta-analysis and mendelian randomization: a review. Res Synth Methods 10:486–496
- Lopera-Maya EA, Kurilshikov A, van der Graaf A, Hu S, Andreu-Sánchez S, Chen L, Vila AV, Gacesa R, Sinha T, Collij V et al (2022) Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat Genet 54:143–151
- 23. Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, Sole G, Lai S, Dei M, Mulas A et al (2020) Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet 52:1036–1045
- 24. Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman ÅK, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J et al (2023) Genetics of

circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 24:1540–1551

- Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA et al (2023) FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613:508–518
- Lan Z, Wei Y, Yue K, He R, Jiang Z (2024) Genetically predicted immune cells mediate the association between gut microbiota and neuropathy pain. Inflammopharmacology
- Burgess S, Small DS, Thompson SG (2017) A review of instrumental variable estimators for mendelian randomization. Stat Methods Med Res 26:2333–2355
- Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, Kazmi N, Robinson TM, Albanes D, Aleksandrova K et al (2020) Physical activity and risks of breast and colorectal cancer: a mendelian randomisation analysis. Nat Commun 11:597
- Bowden J, Del Greco MF, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, Thompson J, Davey Smith G (2019) Improving the accuracy of two-sample summary-data mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol 48:728–742
- Burgess S, Butterworth A, Thompson SG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37:658–665
- Zhang Y, Liu Z, Choudhury T, Cornelis MC, Liu W (2021) Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample mendelian randomization study. Eur J Nutr 60:1761–1767
- Hartwig FP, Davey Smith G, Bowden J (2017) Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46:1985–1998
- Burgess S, Thompson SG (2017) Interpreting findings from mendelian randomization using the MR-Egger method. Eur J Epidemiol 32:377–389
- Ye T, Shao J, Kang H (2021) Debiased inverse-variance weighted estimator in two-sample summary-data mendelian randomization. Annals Stat 49:2079–2100
- SCORE URAP (2018) Statistical inference in two-sample summary-data mendelian randomization using robust adjusted profile score. arXiv Preprint arXiv :180109652
- Verbanck M, Chen CY, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet 50:693–698
- Hemani G, Tilling K, Davey Smith G (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 13:e1007081
- MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V (2002) A comparison of methods to test mediation and other intervening variable effects. Psychol Methods 7:83–104
- Jiao B, Cao X, Zhang C, Zhang W, Yu S, Zhang M, Zhang X (2023) Alterations of the gut microbiota in patients with postherpetic neuralgia. AMB Express 13:108
- Freidin MB, Stalteri MA, Wells PM, Lachance G, Baleanu AF, Bowyer RCE, Kurilshikov A, Zhernakova A, Steves CJ, Williams FMK (2021) An association between chronic widespread pain and the gut microbiome. Rheumatology (Oxford) 60:3727–3737
- Goudman L, Demuyser T, Pilitsis JG, Billot M, Roulaud M, Rigoard P, Moens M (2024) Gut dysbiosis in patients with chronic pain: a systematic review and meta-analysis. Front Immunol 15:1342833
- Hall LJ, Walshaw J, Watson AJ (2014) Gut microbiome in new-onset Crohn's disease. Gastroenterology 147:932–934
- Quiroga R, Nistal E, Estébanez B, Porras D, Juárez-Fernández M, Martínez-Flórez S, García-Mediavilla MV, de Paz JA, González-Gallego J, Sánchez-Campos S, Cuevas MJ (2020) Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. Exp Mol Med 52:1048–1061
- Nie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X (2021) Roseburia intestinalis: a beneficial gut organism from the discoveries in Genus and Species. Front Cell Infect Microbiol 11:757718
- Jalanka-Tuovinen J, Salonen A, Nikkilä J, Immonen O, Kekkonen R, Lahti L, Palva A, de Vos WM (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE 6:e23035
- 46. Yu M, Li L, Ren Q, Feng H, Tao S, Cheng L, Ma L, Gou SJ, Fu P (2022) Understanding the gut-kidney Axis in Antineutrophil Cytoplasmic

Antibody-Associated Vasculitis: an analysis of gut microbiota composition. Front Pharmacol 13:783679

- 47. Wei Y, Lu X, Liu C (2023) Gut microbiota and chronic obstructive pulmonary disease: a mendelian randomization study. Front Microbiol 14:1196751
- Dekker Nitert M, Mousa A, Barrett HL, Naderpoor N, de Courten B (2020) Altered gut microbiota composition is Associated with Back Pain in overweight and obese individuals. Front Endocrinol (Lausanne) 11:605
- Ellis RJ, Heaton RK, Gianella S, Rahman G, Knight R (2022) Reduced gut microbiome diversity in people with HIV who have Distal Neuropathic Pain. J Pain 23:318–325
- Hadizadeh F, Bonfiglio F, Belheouane M, Vallier M, Sauer S, Bang C, Bujanda L, Andreasson A, Agreus L, Engstrand L et al (2018) Faecal microbiota composition associates with abdominal pain in the general population. Gut 67:778–779
- Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N (2019) Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol 46:595–603
- 52. Wang Z, Guo M, Li J, Jiang C, Yang S, Zheng S, Li M, Ai X, Xu X, Zhang W et al (2023) Composition and functional profiles of gut microbiota reflect the treatment stage, severity, and etiology of acute pancreatitis. Microbiol Spectr 11:e0082923
- 53. Shen CL, Wang R, Ji G, Elmassry MM, Zabet-Moghaddam M, Vellers H, Hamood AN, Gong X, Mirzaei P, Sang S, Neugebauer V (2022) Dietary supplementation of gingerols- and shogaols-enriched ginger root extract attenuate pain-associated behaviors while modulating gut microbiota and metabolites in rats with spinal nerve ligation. J Nutr Biochem 100:108904
- Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín JL, van Liempd S, Cabrera D, Royo F, Valero A, Errazquin N et al (2019) Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia. EBioMedicine 46:499–511
- Li JS, Su SL, Xu Z, Zhao LH, Fan RY, Guo JM, Qian DW, Duan JA (2022) Potential roles of gut microbiota and microbial metabolites in chronic inflammatory pain and the mechanisms of therapy drugs. Ther Adv Chronic Dis 13:20406223221091177
- Michalak A, Mosińska P, Fichna J (2016) Polyunsaturated fatty acids and their derivatives: therapeutic value for Inflammatory, Functional Gastrointestinal disorders, and Colorectal Cancer. Front Pharmacol 7:459
- Xiang W, Lv H, Xing F, Sun X, Ma Y, Wu L, Lv G, Zong Q, Wang L, Wu Z et al (2023) Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. Sci Adv 9:eadi2465
- Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM (2011) LPS sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. J Dent Res 90:759–764
- 59. Boonen B, Alpizar YA, Meseguer VM, Talavera K (2018) TRP Channels as sensors of bacterial endotoxins. Toxins (Basel) 10
- 60. Hemmi H, Akira S (2005) TLR signalling and the function of dendritic cells. Chem Immunol Allergy 86:120–135
- Laumet G, Edralin JD, Dantzer R, Heijnen CJ, Kavelaars A (2019) Cisplatin educates CD8 + T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice. Pain 160:1459–1468
- Austin PJ, Kim CF, Perera CJ, Moalem-Taylor G (2012) Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. Pain 153:1916–1931
- Cheadle WG (1993) The human leukocyte antigens and their relationship to infection. Am J Surg 165:75s–81s
- 64. Ji RR, Xu ZZ, Gao YJ (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13:533–548
- Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR (2010) Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 16:592–597 591p following 597
- Willemen HL, Eijkelkamp N, Garza Carbajal A, Wang H, Mack M, Zijlstra J, Heijnen CJ, Kavelaars A (2014) Monocytes/Macrophages control resolution of transient inflammatory pain. J Pain 15:496–506
- 67. Wang Z, Song K, Zhao W, Zhao Z (2020) Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. Bioengineered 11:661–678
- Rausch T, Wachter A (2005) Sulfur metabolism: a versatile platform for launching defence operations. Trends Plant Sci 10:503–509
- 69. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I et al (2011) Fumarates improve

psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291–2303
Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione

 Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 95:3071–3076

# **Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.